… from the FDA on June 25, 2018
The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. This is the first FDA-approved drug that contains a purified drug substance derived from marijuana. It is also the first FDA approval of a drug for the treatment of patients with Dravet syndrome.
What is CBD?
CBD is a cannabinoid, which is a compound found in cannabis plants. There are upwards of 100 cannabinoids within the plant, including CBD and THC (the one that gets you high). CBD is shorthand for cannabidiol; THC, the psychoactive compound, is shorthand for tetrahydrocannabinol. Most CBD products on the market right now come from hemp, which is a variety of the cannabis plant that has less than .3 percent THC. (The marijuana variety, on the other hand, has a higher THC count that varies depending on the strain.) You’ll often see it referred to as “industrial hemp” to distinguish that it’s legal in all states.
Read the whole FDA release HERE
As always we hope this information was helpful.